Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An image-based CRISPR screen reveals splicing-mediated control of HP1α condensates.

bioRxiv : the preprint server for biology·2026
Same author

Correction: Quantitative Proteomics Links the LRRC59 Interactome to mRNA Translation on the ER Membrane.

Molecular & cellular proteomics : MCP·2026
Same author

Attempts to Achieve Targeted Covalent Inhibition of Hsp90β.

Chemical biology & drug design·2026
Same author

Cell-Impermeable Hsp90α-Selective Inhibitor NDNA4 Inhibits Cancer Cell Migration and Targets Extracellular Hsp90α's Critical F-5 Fragment.

ACS chemical biology·2026
Same author

Desmosomes compartmentalize mRNA and translation in the skin.

Developmental cell·2026
Same author

The evolution of heat shock protein 90 C-terminal inhibitors: From novobiocin to potential clinical candidates.

Cell stress & chaperones·2026

Related Experiment Video

Updated: May 21, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Development of a Grp94 inhibitor.

Adam S Duerfeldt1, Laura B Peterson, Jason C Maynard

  • 1Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66047, USA.

Journal of the American Chemical Society
|May 31, 2012
PubMed
Summary

Targeting Heat Shock Protein 90 (Hsp90) offers cancer treatment potential. A novel inhibitor selectively targets Grp94, an ER-resident Hsp90, avoiding toxic effects seen with pan-Hsp90 inhibitors.

More Related Videos

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
09:49

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Published on: April 29, 2020

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
09:49

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Published on: April 29, 2020

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Heat Shock Protein 90 (Hsp90) is a key therapeutic target for cancer.
  • Current Hsp90 inhibitors cause off-target effects and toxicity due to broad isoform inhibition.
  • Selective inhibition of specific Hsp90 isoforms may overcome these limitations.

Purpose of the Study:

  • To design and synthesize a selective inhibitor of Grp94, the endoplasmic reticulum-resident Hsp90 isoform.
  • To evaluate the effects of the designed inhibitor (compound 2) on Grp94 and cytosolic Hsp90α/β client proteins.
  • To assess the therapeutic potential of selective Grp94 inhibition.

Main Methods:

  • Structure-based drug design approach.
  • Synthesis and chemical characterization of compound 2.
  • In vitro and in vivo assays to assess client protein interactions and biological effects.

Main Results:

  • Compound 2 selectively inhibited Grp94, impacting client proteins like the Toll receptor and IGF-II.
  • Grp94-dependent processes, including Drosophila larval growth, were suppressed by compound 2.
  • Compound 2 showed no significant effect on cell viability or cytosolic Hsp90α/β client proteins at tested concentrations.

Conclusions:

  • Selective Grp94 inhibition is achievable and may offer a safer therapeutic strategy than pan-Hsp90 inhibition.
  • Compound 2 demonstrates the potential of targeting specific Hsp90 isoforms for disease treatment.
  • Further investigation into Grp94-specific inhibitors is warranted for therapeutic development.